Somewhat Favorable News Coverage Somewhat Unlikely to Impact Humana (HUM) Stock Price

Media headlines about Humana (NYSE:HUM) have been trending somewhat positive on Saturday, Accern Sentiment reports. Accern identifies positive and negative press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Humana earned a daily sentiment score of 0.14 on Accern’s scale. Accern also assigned media coverage about the insurance provider an impact score of 47.3369901462853 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Here are some of the headlines that may have impacted Accern Sentiment Analysis’s rankings:

Get Humana alerts:

Humana offers suggestions on how to stay safe during hurricane season (brproud.com) Humana People to People launches Seeds of Africa initiative (newsday.co.zw) Humana Teams up with Jefferson Regional Medical Center and Arkansas Department of Health to Promote … (businesswire.com) Broussard on why Humana invested in primary care startup (bizjournals.com) Humana hiring 100 for phone sales, Medicare enrollment assistance (tampabay.com)

Shares of Humana traded up $0.72, hitting $294.41, during midday trading on Friday, Marketbeat.com reports. The stock had a trading volume of 381,528 shares, compared to its average volume of 750,454. The stock has a market capitalization of $40.44 billion, a PE ratio of 25.14, a PEG ratio of 1.52 and a beta of 0.95. The company has a current ratio of 1.55, a quick ratio of 1.55 and a debt-to-equity ratio of 0.47. Humana has a fifty-two week low of $223.40 and a fifty-two week high of $299.85.

Humana (NYSE:HUM) last announced its quarterly earnings results on Wednesday, May 2nd. The insurance provider reported $3.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.21 by $0.15. The company had revenue of $14.28 billion for the quarter, compared to analyst estimates of $14.22 billion. Humana had a net margin of 3.36% and a return on equity of 16.74%. During the same period in the previous year, the firm posted $2.75 EPS. research analysts predict that Humana will post 13.99 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, July 27th. Investors of record on Friday, June 29th will be issued a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a dividend yield of 0.68%. The ex-dividend date is Thursday, June 28th. Humana’s dividend payout ratio (DPR) is presently 17.08%.

Several analysts have weighed in on HUM shares. ValuEngine upgraded shares of Humana from a “hold” rating to a “buy” rating in a research note on Monday, April 2nd. Zacks Investment Research upgraded shares of Humana from a “hold” rating to a “buy” rating and set a $316.00 price objective for the company in a research note on Friday, April 13th. Cantor Fitzgerald reiterated a “hold” rating and issued a $250.00 price objective on shares of Humana in a research note on Monday, April 23rd. Credit Suisse Group upgraded shares of Humana from a “neutral” rating to an “outperform” rating and dropped their price objective for the stock from $264.90 to $246.00 in a research note on Thursday, February 8th. Finally, Piper Jaffray Companies reiterated a “buy” rating and issued a $313.00 price objective on shares of Humana in a research note on Wednesday, April 4th. Seven investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Humana presently has a consensus rating of “Buy” and an average target price of $280.00.

In related news, CEO Bruce D. Broussard sold 14,075 shares of Humana stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $274.32, for a total transaction of $3,861,054.00. Following the sale, the chief executive officer now directly owns 113,896 shares of the company’s stock, valued at approximately $31,243,950.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Bruce D. Broussard sold 17,604 shares of Humana stock in a transaction that occurred on Thursday, May 3rd. The shares were sold at an average price of $286.17, for a total transaction of $5,037,736.68. Following the sale, the chief executive officer now directly owns 89,259 shares in the company, valued at $25,543,248.03. The disclosure for this sale can be found here. Insiders have sold a total of 69,885 shares of company stock worth $19,601,498 over the last ninety days. 0.60% of the stock is currently owned by insiders.

About Humana

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company operates through four segments: Retail; Group and Specialty; Healthcare Services; and Individual Commercial. The Retail segment offers Medicare and supplemental benefit plans to individuals or through group accounts.

Insider Buying and Selling by Quarter for Humana (NYSE:HUM)

Leave a Reply

Your email address will not be published. Required fields are marked *